Molecular Genomics (Mol G)

Precision medicine relies on understanding the genetic changes that cause cancer development and response to therapy. Cancer is most commonly a disease diagnosed in aging adults, with cancer onset in childhood considered rare. However, this means that it is even more important to investigate the genetic basis of children’s cancer. We are using Next Generation Sequencing and Functional Biology to understand the genetic contributions in the development of childhood cancers.

The research team

Clinical Research specialist: Dr Bhavna Padhye

Genomicist: Dr Dianne Sylvester

Translational biologist: Dr Yuyan Chen

> Other Research Team Members

  • Dr Rose Boutros, Senior Research Officer
  • Ms Bharvi Maneck, Project Officer
  • Dr Federica Saletta, Senior Research Officer
  • Mr Punkaja Maninda S Amarasekera, PhD student
  • Ms Amanda Rush, PhD Student
  • Ms Rachel West, Research assistant

Key publications

The possibility of systematic research fraud targeting under-studied human genes: causes, consequences and potential solutions. Byrne JA, Grima N, Capes-Davis A, Labbé C (2019). Biomarker Insights, in press.

The research perspective on utilizing and valuing tumor biobanks. Rush A, Matzke L, Cooper S, Gedye C, Byrne J, Watson P. Biopreserv Biobank, in press.

Research governance review of a negligible-risk research project: too much of a good thing? Rush A, Ling R, Carpenter JE, Carter C, Searles A, Byrne JA (2018). Res Ethics. 14: 1–12.

An investigation of clinically relevant germline variants detected by next generation sequencing in childhood cancer patients – a review of the literature. Sylvester D, Chen Y, Jamieson RV, Dalla-Pozza L, Byrne JA (2018). J Med Genet. 55: 785-93.

Striking similarities between publications from China describing single gene knockdown experiments in human cancer cell lines. Byrne JA, Labbé C (2017). Scientometrics. 110:1471-93.

PD-L1 expression in a large cohort of pediatric solid tumor patients and association with clinico-pathological features in neuroblastoma.  Saletta F, Vilain RE, Gupta AK, Nagabushan S, Yuksal A, Catchpoole D, Scolyer R, Byrne JA, McCowage G (2017).  JCO Precision Med. 1: 1-12.

Dropping in on the lipid droplet- tumor protein D52 (TPD52) as a new regulator and resident protein.  Chen Y, Frost S, Byrne JA (2016). Adipocyte 5: 326-32.

Quality and reporting practices in an Australian cancer biobank cohortRush A, Byrne JA (2016).  Clin Biochem 49: 492-7.

TPD52 expression increases neutral lipid storage within cultured cells.  Kamili A, Roslan N, Frost S, Cantrill LC, Wang D, Della-Franca A, Bright RK, Groblewski GE, Straub BK, Hoy AJ, Chen Y, Byrne JA (2015). J Cell Sci 128: 3223-38.

Molecular profiling of childhood cancer: biomarkers and novel therapies. Saletta F, Wadham C, Ziegler DS, Marshall GM, Haber M, McCowage G, Norris MD, Byrne JA (2014). BBA Clinical 1: 59-77

For a full list of publications, please click here.